Abstract: 3,4-Dihydro-
Introduction
Since azidothymidine (AZT), a nucleoside reverse transcriptase inhibitor (NRTI), was approved for the treatment of HIV infections, a number of anti-HIV drugs have been launched. For example, saquinavir and nevirapine were the first protease inhibitor and non-nucleoside reverse transcriptase inhibitor (NNRTI), respectively. 1 Highly active antiretroviral therapy (HAART) using a combination of these antiretrovirals is a standard treatment regimen for HIV infections. The HAART regimen significantly reduces viral load in infected patients, leading to significant therapeutic gains and reductions in morbidity and mortality. 2 However, long-term administration of multiple antiretrovirals to maintain life-long latent infection triggers the emergence of drug-resistant variants 3 and drug-related adverse effects. 4 For example, high-level viral resistance to NRTI such as AZT, stavudine, and didanosine is conferred by mutations frequently observed in patients with virologic failure on an NRTI-containing regimen. 5 In addition, lipodystrophy and metabolic disorders are often observed in patients receiving HIV protease inhibitors. 6 To overcome these problems, several antiretrovirals with new mechanisms of action have been developed in this decade. A peptide-based fusion inhibitor (enfuvirtide), combination regimen(s) of anti-HIV agents for the treatment of drug-resistant variants.
In our efforts to develop novel anti-HIV compounds, 13 we have carried out the random screening of small molecules using multinuclear activation of a galactosidase indicator (MAGI) assay, in which the inhibitory activity of early-stage HIV infection, including virus attachment and membrane fusion to host cells, is evaluated. Among more than 30,000 compounds screened, 3,4-dihydro-2H,6H-pyrimido [1,2-c] [1, 3] benzothiazin-6-imine 4 (PD 404182) was identified as a potent anti-HIV agent lead ( Figure 1 ). Compound 4 was reported to be an enzyme inhibitor against 3-deoxy-D-manno-octulosonic acid 8-phosphate synthase 14 and phosphopantetheinyl transferase, 15 exerting antimicrobial effects. In the course of our SAR investigations in this study, antiviral activities of 4 against HCV, HIV, and simian immunodeficiency virus were reported. 16, 17 Although compound 4 exhibits virucidal effects at high concentrations, the mechanism of action and the target molecule remain ambiguous. 17 Recently, we have established two independent approaches for the synthesis of PD 404182 derivatives (Scheme 1): C-H functionalization of 2-phenyl-1,4,5,6-tetrahydropyrimidine with water or t-butylcarbamate in the presence of copper(II) acetate provides pyrimido [1,2-c] [1, 3] benzoxazine or pyrimido [1,2-c] quinazoline in one or two step(s) (Eq. 1, Scheme 1).
Results and discussion

Strategy for the SAR study of PD 404182
PD 404182 consists of three components, namely a 1,3-thiazin-2-imine core, and left-fused benzene and cyclic amidine moieties (Figure 2) . In order to obtain detailed insights into the relationships between the compound structure and anti-HIV activity, we planned to investigate substituent effects on each component: (I) derivatives with various heteroatom (N, S, and O) arrangements on the 1,3-thiazin-2-imine core ( Figure 2) ; (II) pyrimido [1,2-c] [1, 3] thiazin-6-imine derivatives fused with a substituted benzene ring or a five-or six-membered aromatic heterocycle; and (III) benzo[e] [1, 3] thiazin-2-imine derivatives fused with a cyclic amidine ring with or without accessory alkyl or aryl groups.
Synthesis of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles
Our investigation began with the synthesis of tricyclic heterocycles with different combinations of heteroatoms on the 1,3-thiazin-2-imine core. Previously, we reported syntheses of pyrimido [1,2-c] [1, 3] benzoxazine and pyrimido [1,2-c] quinazoline derivatives using as demonstrated in our previous report (Scheme 2).
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Subsequent treatment with Lawesson's reagent led to formation of the thiocarbonyl derivative 11. Since no hydrolysis of the carbonyl or thiocarbonyl group of compound 10 or 11 for construction of the 2-aminoquinazoline structure in 12 occurred, an alternative approach starting from 2-aminobenzyl alcohol 15 was used for the synthesis of the 2-aminoquinazoline derivative 12 (Scheme 3). After protection and PCC oxidation of 15, oxidative amidination 21 provided 2-(p-tosylamino)phenyltetrahydropyrimidine 17. Deprotection followed by BrCN-mediated cyclization of 17 provided the expected 2-aminoquinazoline derivative
12.
For the synthesis of pyrimido [1,2-c] [1, 3] benzothiazine derivatives, we adapted the C-H functionalization reaction for C-S bond formation (Scheme 2). After optimization of the reaction conditions, we found that exposure of compound 5 to CS2 in the presence of Cu(OAc)2 directly afforded a pyrimido [1,2-c] [1, 3] benzothiazine-6-thione scaffold 13. Hydrolysis of the thiocarbonyl group in 13 followed by treatment with BrCN or triphosgene provided 6-imino or 6-oxo derivatives thiazinimine derivatives 25-27, which were treated with TFA to provide the expected products
28-30.
The intermediates 25e, 25k, and 26k were subjected to further manipulations to obtain the functionalized derivatives (Scheme 5). The nitro group of 25e was reduced by hydrogenation to form the 9-amino derivative 31. Alkylation of 31 afforded the 9-(N-methylamino) derivative 25b (Eq. 1, Scheme 5). The 9-acetamide derivative 25c was obtained by treatment of 31 with acetic anhydride (Eq. 2, Scheme 5). Sandmeyer reaction of 31 gave the 9-azide derivative 25p (Eq. 3, Scheme 5).
Me2N-and MeO-substituted derivatives (25a, 26a, and 26f) were obtained by Me2NH-mediated
N-arylation
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of the 9-bromo 25k and 10-bromo derivatives 26k, and NaOMe-mediated Ullmann 
Synthesis of benzo[e][1,3]thiazine derivatives with fused cyclic amidines
Benzo[e] [1, 3] thiazine derivatives with various ring-sized and/or modified cyclic amidine moieties 35 were also synthesized by the consecutive heterocumulene addition and SNAr reactions (Scheme 6). Oxidative amidination using several diamines 32 proceeded efficiently to form five-or six-membered rings (33a-d). The same reaction for the seven-membered amidine (33e) was incomplete, but purification of the Boc-protected amidine 36 followed by subsequent deprotection of the Boc group gave the pure seven-membered amidine 33e. The resulting amidines were converted to cyclic-amidine-fused benzo[e] [1, 3] Initially, the structural requirements of the 1,3-thiazin-2-imine core substructure in 4 (PD 404182) for anti-HIV activity were investigated ( Table 1 ). The antiviral activities against the HIV-1IIIB strain were evaluated using the MAGI assay. Substitution of the imino group in 4 with a carbonyl group (14) resulted in a significant decrease in anti-HIV activity (EC50 = 8.94 M).
Pyrimido [1,2-c] [1, 3] benzoxazines (7-9), pyrimido [1,2-c] quinazolines (10) (11) (12) , and pyrimido [1,2-c] [1, 3] benzothiazine-6-thione (13), in which the 1-sulfur and/or 2-imino groups in 4
were modified, showed no activity. These results suggested that both the 1-sulfur atom and the 2-imino group are indispensable functional groups for the inhibitory activity against HIV infection, and may be involved in potential interactions with the target molecules. A series of derivatives with modification of the benzene substructure in the pyrimido [1,2-c] [1, 3] benzothiazine were evaluated for anti-HIV activity ( Table 2 ). The addition of positively charged N, N-dimethylamino (28a) and N-methylamino groups (28b) at the 9-position significantly decreased the anti-HIV activity. The 9-acetamide group (28c), which has hydrogen-bond donor/acceptor abilities, also attenuated the bioactivity. The acetyl (28d) and nitro (28e) groups, with hydrogen acceptor properties, induced slight decreases in the anti-HIV activity. In contrast, derivatives with less-polarized substituents (28f-o and 28q) at this position generally reproduced the potent anti-HIV activity of 4. In terms of the electron-donating or -withdrawing properties of the substituent groups on the benzene substructure, good correlations were not observed.
For example, the electron-donating methoxy (28f), methyl (28g), and n-butyl groups (28h), and the electron-withdrawing fluoro (28i) and trifluoromethyl groups (28j) exhibited similar anti-HIV activities (EC50 = 0.44 -0.57 M), indicating that the antiviral activity is independent of the electronic state of the 1,3-benzothiazin-2-imine core in forming potential -stacking interaction(s) with the target molecules. Among the hydrophobic substituents at this position, bromo (28k), phenyl (28l), vinyl (28m), styryl (28n), and pentenyl groups (28o) induced inhibitory activity two or three times greater than that of 4 (EC50 = 0.18 -0.25 M). Modification with photoreactive azido (28p) and benzoylphenyl groups (28q) maintained the inhibitory activity; these could be used as probe molecules to identify the target molecule(s) of 4. Further miscellaneous modifications of benzothiazine substructure were also investigated ( Table 2 ). The naphtho [2,3-e] [1, 3] thiazine derivative 30r, with a 9,10-fused benzene, exhibited anti-HIV activity equipotent to that of the parent 4 (EC50 = 0.56 M). A 6-fold decrease in the anti-HIV activity of the pyridine-fused pyrido [3,2-e] [1, 3] thiazine derivative (30s) was observed (EC50 = 2.55 M). In addition, introduction of 8-bromo (30k) and 8,9-fused benzene (30t, ,3] thiazine) substituents on benzothiazine resulted in a loss of activity, suggesting that modification at the 8-position was inappropriate for favorable interactions with the target molecule(s). The 11-fluoro derivative 30i and thiophene-fused 30u, which has a 5-6-6 framework (thieno [2,3-e] [1, 3] thiazine), exhibited four times lower and no inhibitory potencies, respectively.
Structure-activity relationships of cyclic amidine part of pyrimido[1,2-c][1,3]benzothiazine
A SAR study of the top-right cyclic amidine substructure was carried out. The five-membered dihydroimidazole derivative 35a had no anti-HIV activity ( Table 3 To gain additional insights into the mechanism of action of PD 404182 derivatives, the antiviral activities against other HIV subtypes were evaluated (Table 4) Optimization studies of the benzene and cyclic amidine rings indicate that the introduction of a hydrophobic group on the benzene ring and the amidine group is more effective in improving the antiviral activity, giving potential favorable interaction(s) with the target molecule(s). In addition, PD 404182 derivatives could be promising agents for treatment of HIV-2 infection. We also revealed, using time of drug addition experiments, that PD 404182 derivatives prevent the HIV infection process at an early stage. For iterative molecular design of more effective derivatives based on binding modes, the identification of the target molecule(s) of PD 404182 derivatives is being investigated using derivatives such as 28p and 28q.
Experimental section
General 1 H NMR spectra were recorded using a JEOL AL-400 or a JEOL ECA-500 spectrometer.
Chemical shifts are reported in δ (ppm) relative to Me4Si as an internal standard. propylenediamine (285.4 mg, 3.9 mmol). The mixture was stirred at 70 °C for 30 min, and then K2CO3 (1.45 g, 10.5 mmol) and I2 (1.11 g, 4.4 mmol) were added. After being stirred at same temperature for 3 h, the mixture was quenched with sat. Na2SO3. The organic layer was separated and concentrated. The resulting solid was dissolved in H2O, and then pH was adjusted to 12-14 with 2N NaOH. The whole was extracted with CHCl3. The extract was dried over MgSO4. After concentration, the resulting solid was recrystallized from CHCl3-n-hexane to give compound 23k as colorless crystals (0.62 g, 69%): mp 99 °C; IR (neat)max/cm . δC (100 MHz; CDCl3) 21.5, 45.0, 48.5, 122.3, 128.4, 130.8, 131.0, 141.7 and 189.7 1, 21.1, 43.8, 44.9, 123.6, 124.1, 127.4, 128.6, 128.8, 141.1, 146.6 and 153.6 
3,4-dihydro-2H,6H-pyrimido[1,2-c]thieno[2,3-e][1,3]thiazin-6-thione (24u)
.
Determination of anti-HIV activity
The sensitivity of three HIV-1 strains and two HIV-2 strains was determined by the MAGI assay. [1,2-c] [1, 3] thiazin-6-imine derivatives fused with substituted benzene and heterocycles (28) (29) (30) 
